These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration. Totsuka M; Miyashita Y; Ito Y; Watanabe H; Murano T; Shirai K Atherosclerosis; 2000 Nov; 153(1):175-9. PubMed ID: 11058713 [TBL] [Abstract][Full Text] [Related]
5. Lipid profiles on fibric-acid derivatives. Capps NE Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370 [No Abstract] [Full Text] [Related]
6. Normocholesterolaemic dyslipidaemia: is there a role for fibrates? Watts GF; Dimmitt SB; Barter PJ Med J Aust; 2001 Jan; 174(2):66-7. PubMed ID: 11245504 [No Abstract] [Full Text] [Related]
7. [Overviews of fibrate]. Tada N Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141 [No Abstract] [Full Text] [Related]
8. Trials of the effects of drugs and hormones on lipids and lipoproteins. Mann WA; Windler E; Beil FU; Greten H Curr Opin Lipidol; 1995 Dec; 6(6):354-9. PubMed ID: 8750247 [TBL] [Abstract][Full Text] [Related]
9. Long term improvement in dyslipidaemia in Type 2 diabetes with bezafibrate is not related to changes in insulin resistance. Elkeles RS; Diamond JR; Anyaoku V; Hughes C; Richmond W Atherosclerosis; 1999 Sep; 146(1):195-6. PubMed ID: 10487504 [No Abstract] [Full Text] [Related]
10. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis. Kawano M; Kuroda Y; Terao M; Yaginuma T; Kawakami M; Kanazawa Y Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117 [TBL] [Abstract][Full Text] [Related]
15. Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism? Shepherd J; Olsson AG; Sacks FM; Black DM; Orloff DG; Bilheimer DW Am J Cardiol; 1998 Apr; 81(8A):88F-94F. PubMed ID: 9604922 [No Abstract] [Full Text] [Related]
16. Lipids and Cardiovascular Disease: Putting It All Together. Pownall HJ; Gotto AM Methodist Debakey Cardiovasc J; 2019; 15(1):5-8. PubMed ID: 31049143 [No Abstract] [Full Text] [Related]
17. Paradoxical high-density lipoprotein reduction induced by fibrate therapy. Oleesky DA; Mir MA Ann Clin Biochem; 1997 Sep; 34 ( Pt 5)():573-4. PubMed ID: 9293321 [No Abstract] [Full Text] [Related]
18. A case for lipid-lowering? Durrington P Diabet Med; 2000 Sep; 17 Suppl 2():4-5. PubMed ID: 11048824 [No Abstract] [Full Text] [Related]
19. Re: Gómez-Gerique, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002;162:245-51. Moriarty PM; Backes JM Atherosclerosis; 2003 Jan; 166(1):201. PubMed ID: 12564455 [No Abstract] [Full Text] [Related]
20. Recommendations for the treatment of lipid disorders in patients on peritoneal dialysis. ISPD guidelines/recommendations. International Society for Peritoneal Dialysis. Fried L; Hutchison A; Stegmayr B; Prichard S; Bargman JM Perit Dial Int; 1999; 19(1):7-16. PubMed ID: 10201335 [No Abstract] [Full Text] [Related] [Next] [New Search]